Prevalence and clinicopathological characteristics of islet amyloid in chinese patients with type 2 diabetes

被引:96
|
作者
Zhao, HL [1 ]
Lai, FMM
Tong, PCY
Zhong, DR
Yang, D
Tomlinson, B
Chan, JCN
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Pathol, Beijing, Peoples R China
[4] Peking Union Coll Hosp, Dept Pathol, Beijing, Peoples R China
关键词
D O I
10.2337/diabetes.52.11.2759
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Islet amyloid has been suggested to be an important link between insulin resistance and R-cell dysfunction in type 2 diabetes. To investigate the prevalence and clinicopathological characteristics of islet amyloid, we examined consecutive autopsies of 235 Chinese patients with type 2 diabetes and 533 nondiabetic subjects. Islet amyloid deposits were identified using Congo red staining and quantitated by image analysis. We found that 3.0% of the nondiabetic subjects versus 39.6% of the diabetic patients displayed islet amyloid (P < 0.001). In diabetic patients, the amyloid deposits occupied a mean islet area of 36.2%, which was positively associated with BMI, blood pressure, and glycemic control. Pancreatic fibrosis and fat infiltration were more frequently found in diabetic patients with islet amyloid than those without islet amyloid, whereas pancreatic arteriosclerosis was identified in all diabetic patients. These findings suggest that islet amyloid deposits reflect greater insulin resistance and islet failure in a subgroup of type 2 diabetic patients. Islet failure may also have been exacerbated by fat infiltration, fibrosis, and arteriosclerosis. Optimal blood pressure and metabolic control may reduce these pathological changes and help preserve islet cell mass.
引用
收藏
页码:2759 / 2766
页数:8
相关论文
共 50 条
  • [31] Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma
    Difan Zheng
    Rui Wang
    Yunjian Pan
    Shanbo Zheng
    Yang Zhang
    Hang Li
    Chao Cheng
    Ranxia Gong
    Yuan Li
    Xuxia Shen
    Haichuan Hu
    Deng Cai
    Xinghua Cheng
    Yihua Sun
    Haiquan Chen
    Annals of Surgical Oncology, 2015, 22 : 1284 - 1291
  • [32] Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma
    Zheng, Difan
    Wang, Rui
    Pan, Yunjian
    Zheng, Shanbo
    Zhang, Yang
    Li, Hang
    Cheng, Chao
    Gong, Ranxia
    Li, Yuan
    Shen, Xuxia
    Hu, Haichuan
    Cai, Deng
    Cheng, Xinghua
    Sun, Yihua
    Chen, Haiquan
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S1284 - S1291
  • [33] Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma
    Shan, Ling
    Qiu, Tian
    Ling, Yun
    Guo, Lei
    Zheng, Bo
    Wang, Bingning
    Li, Wenbin
    Li, Lin
    Ying, Jianming
    PLOS ONE, 2015, 10 (06):
  • [34] Clinicopathologic characteristics of nodular glomerulosclerosis in Chinese patients with type 2 diabetes
    Zhao, HL
    Lai, FMM
    Tong, PCY
    Tomlinson, B
    Chan, JCN
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 44 (06) : 1039 - 1049
  • [35] ISLET AMYLOID AND TYPE-2 (NON-INSULIN-DEPENDENT) DIABETES
    CLARK, A
    SOUTH AFRICAN MEDICAL JOURNAL, 1990, : 7 - 11
  • [36] ISLET AMYLOID POLYPEPTIDE - HEN OR EGG IN TYPE-2 DIABETES PATHOGENESIS
    BETSHOLTZ, C
    CHRISTMANSON, L
    GEBREMEDHIN, S
    WESTERMARK, P
    ACTA ONCOLOGICA, 1993, 32 (02) : 149 - 154
  • [37] Survival of an islet β-cell in type 2 diabetes Curbing the effects of amyloid cytotoxicity
    Loomes, Kerry M.
    ISLETS, 2011, 3 (01) : 38 - 39
  • [38] Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes
    Matveyenko, Aleksey V.
    Butler, Peter C.
    ILAR JOURNAL, 2006, 47 (03) : 225 - 233
  • [39] Inhibitors of islet amyloid polypeptide fibrillogenesis, and the treatment of type-2 diabetes
    Scrocchi, LA
    Chen, Y
    Wang, F
    Han, K
    Ha, K
    Wu, L
    Fraser, PE
    LETTERS IN PEPTIDE SCIENCE, 2003, 10 (5-6): : 545 - 551
  • [40] Inhibitors of islet amyloid polypeptide fibrillogenesis, and the treatment of type-2 diabetes
    Louise A. Scrocchi
    Yan Chen
    Feng Wang
    Kyung Han
    Katherine Ha
    Ling Wu
    Paul E. Fraser
    Letters in Peptide Science, 2003, 10 : 545 - 551